Company Analysis Exact Sciences Corporation
1. Summary
Advantages
- Price (68.37 $) is less than fair price (73.84 $)
- The stock's return over the last year (-2.05%) is higher than the sector average (-48.03%).
Disadvantages
- Dividends (0%) are below the sector average (0.5339%).
- Current debt level 46.47% has increased over 5 years from 26.96%.
- The company's current efficiency (ROE=-37.09%) is lower than the sector average (ROE=103.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Exact Sciences Corporation | Healthcare | Index | |
|---|---|---|---|
| 7 days | 1.7% | -36.2% | 0.5% |
| 90 days | 49.9% | -47.8% | 7.7% |
| 1 year | -2% | -48% | 18.9% |
EXAS vs Sector: Exact Sciences Corporation has outperformed the "Healthcare" sector by 45.98% over the past year.
EXAS vs Market: Exact Sciences Corporation has significantly underperformed the market by -20.94% over the past year.
Stable price: EXAS is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: EXAS with weekly volatility of -0.0394% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (68.37 $) is lower than the fair price (73.84 $).
Price not significantly lower than the fair price: The current price (68.37 $) is slightly lower than the fair price by 8%.
5.2. P/E
P/E vs Sector: The company's P/E (-7.47) is higher than that of the sector as a whole (-274.25).
P/E vs Market: The company's P/E (-7.47) is higher than that of the market as a whole (-80.5).
5.3. P/BV
P/BV vs Sector: The company's P/BV (4.31) is lower than that of the sector as a whole (256.7).
P/BV vs Market: The company's P/BV (4.31) is lower than that of the market as a whole (51.89).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (3.75) is lower than that of the sector as a whole (56.99).
P/S vs Market: The company's P/S indicator (3.75) is lower than that of the market as a whole (137.42).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-15.86) is lower than that of the sector as a whole (12.51).
EV/Ebitda vs Market: The company's EV/Ebitda (-15.86) is higher than that of the market as a whole (-47.95).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 4.25% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (4.25%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-22.73%).
6.4. ROE
ROE vs Sector: The company's ROE (-37.09%) is lower than that of the sector as a whole (103.63%).
ROE vs Market: The company's ROE (-37.09%) is lower than that of the market as a whole (-10.25%).
6.6. ROA
ROA vs Sector: The company's ROA (-16.6%) is lower than that of the sector as a whole (-2.84%).
ROA vs Market: The company's ROA (-16.6%) is lower than that of the market as a whole (39.65%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-12.57%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (-12.57%) is lower than that of the market as a whole (8.73%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5339%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Selling More insider purchases by 768% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 19.11.2025 | ORVILLE JACOB A Officer |
Purchase | 75 | 37 500 | 5 000 |
| 24.10.2025 | Zanotti Katherine S Director |
Sale | 65 | 78 000 | 12 000 |
| 09.10.2025 | Doyle James Edward Director |
Sale | 60 | 120 000 | 2 000 |
| 09.10.2025 | Herriott James SVP, General Counsel & Sec |
Sale | 60 | 90 000 | 1 500 |
| 01.05.2024 | Conroy Kevin T President and CEO |
Sale | 60.15 | 69 473 | 1 155 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
